Financiado en parte por Eli Lilly and Company, Pfizer, Sanofi, Pharmavite, Meat and Livestock Australia, Servier, DSM, DSM Nutritional Products, Cilag
International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder
Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, Jacka F, Pariante C, Berk M, Marx W, Su KP
Psychotherapy and psychosomatics · 133 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Organización sin fines de lucro
- Wilson Foundation
- Empresa
- Eli Lilly and Company
- Empresa
- Pfizer
- Empresa
- Sanofi
- Universidad u hospital
- Massachusetts General Hospital
- Empresa
- Pharmavite
- Organización sin fines de lucro
- Geelong Region Medical Research Foundation
- Organización sin fines de lucro
- National Alliance for Research on Schizophrenia and Depression
- Organización sin fines de lucro
- David and Elaine Potter Foundation
- Organización sin fines de lucro
- Australian Rotary Health
- Organización sin fines de lucro
- Ian Potter Foundation
- Grupo de la industria
- Meat and Livestock Australia
- Universidad u hospital
- University of Melbourne
- Gobierno
- Ministry of Science and Technology, Taiwan
- Gobierno
- National Health Research Institutes
- Universidad u hospital
- China Medical University
- Empresa
- Servier
- Universidad u hospital
- China Medical University, Taiwan
- Organización sin fines de lucro
- Fernwood Foundation
- Empresa
- DSM
- Gobierno
- National Institutes of Health
- Gobierno
- Medical Research Council
- Gobierno
- National Health and Medical Research Council
- Gobierno
- Japan Society for the Promotion of Science
- Universidad u hospital
- Brain and Behaviour Research Institute, University of Wollongong
- Empresa
- DSM Nutritional Products
- Gobierno
- National Institute of Mental Health
- Gobierno
- Division of Materials Research
- Empresa
- Cilag
- Subvenciones
- National Health Research Institutes (DMR-107-091); Ministry of Science and Technology, Taiwan (NHRI-EX106-10528NI); National Health Research Institutes (CRS-108-048); China Medical University, Taiwan (CRS - 108-048); University of Melbourne (1108125); National Health Research Institutes (NHRI-EX106-10528NI); China Medical University, Taiwan (DMR-107-091); Ministry of Science and Technology, Taiwan (105-2918-I-039-001;); China Medical University, Taiwan (DMR-107-202); China Medical University, Taiwan (CRS-106-063); Ministry of Science and Technology, Taiwan (MOST106-2314-B039-035); China Medical University, Taiwan (DMR-107-204); National Health Research Institutes (CRS-106-063); Ministry of Science and Technology, Taiwan (MOST 107?); National Health Research Institutes (DMR-107-204); National Health Research Institutes (CRS-106-063, DMR-107-202); Japan Society for the Promotion of Science (17H04253); Ministry of Science and Technology, Taiwan (MOST106-2314-B038-049); National Health Research Institutes (DRM-107-097); Ministry of Science and Technology, Taiwan (MOST 108-); Ministry of Science and Technology, Taiwan (MOST108-2320-B039-048); Ministry of Science and Technology, Taiwan (MOST106-2314-B039-027-MY3); Ministry of Science and Technology, Taiwan (MOST108-2314-B039-016); National Health Research Institutes (EX106); National Health Research Institutes (DMR-107-202); China Medical University, Taiwan (DRM-107-097); Ministry of Science and Technology, Taiwan (MOST106-2314-B039-031); National Health and Medical Research Council (1108125)
Según 29 financiadores declarados.
Publicación
- Publicado
- 2019-01-01 · Psychother Psychosom · vol. 88 · número 5 · págs. 263–273
- Editorial
- Karger Publishers
- Citado
- 199 citas · más que el 99% de estudios similares · 13.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 85 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Alcoholism and Thiamine Deficiency · Diet and metabolism studies · Tryptophan and brain disorders
- Palabras clave
- Major depressive disorder, Guideline, Medicine, Psychiatry, Psychopathology, Eicosapentaenoic acid, Polyunsaturated fatty acid, Mood, Fatty acid
- MeSH
- humans, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, antidepressive agents, pregnancy, aged, child, societies, medical, female, biomarkers, major depressive disorder
15 autores
- Ta‐Wei Guu🇹🇼China Medical University; China Medical University Beigang Hospital; China Medical University Hospital
- David Mischoulon🇺🇸Harvard University; Massachusetts General Hospital
- Jerome J. Sarris🇦🇺The University of Melbourne; Westmead Institute; Melbourne Clinic; Western Sydney University
- Joseph R. Hibbeln🇺🇸National Institute on Alcohol Abuse and Alcoholism
- Robert K. McNamara🇺🇸University of Cincinnati Medical Center
- Kei Hamazaki🇯🇵University of Toyama
- Marlene P. Freeman🇺🇸Massachusetts General Hospital; Baim Institute for Clinical Research
- Michael H. J. Maes🇹🇭Chulalongkorn University
- Yutaka Matsuoka🇯🇵National Center for Global Health and Medicine
- Robert Haim Belmaker🇮🇱Ben-Gurion University of the Negev
- Felice Nellie Jacka🇦🇺Deakin University
- Carmine Maria Pariante🇬🇧King's College London
- Michael Berk🇦🇺The University of Melbourne
- Wolfgang Marx🇦🇺Deakin University
- Kuan‐Pin Su🇹🇼China Medical University; China Medical University Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Major depressive disorder (MDD) is a complex mental illness with unmet therapeutic needs. The antidepressant effects of ω-3 polyunsaturated fatty acids (n-3 PUFAs) have been widely reported. The subcommittee of the International Society for Nutritional Psychiatry Research organized an expert panel and conducted a literature review and a Delphi process to develop a consensus-based practice guideline for clinical use of n-3 PUFAs in MDD. The guideline focuses on 5 thematic areas: general concepts, acute treatment strategy, depression recurrence monitoring and prevention, use in special populations, and potential safety issues. The key practice guidelines contend that: (1) clinicians and other practitioners are advised to conduct a clinical interview to validate clinical diagnoses, physical conditions, and measurement-based psychopathological assessments in the therapeutic settings when recommending n-3 PUFAs in depression treatment; (2) with respect to formulation and dosage, both pure eicosapentaenoic acid (EPA) or an EPA/docosahexaenoic acid (DHA) combination of a ratio higher than 2 (EPA/DHA >2) are considered effective, and the recommended dosages should be 1-2 g of net EPA daily, from either pure EPA or an EPA/DHA (>2:1) formula; (3) the quality of n-3 PUFAs may affect therapeutic activity; and (4) potential adverse effects, such as gastrointestinal and dermatological conditions, should be monitored, as well as obtaining comprehensive metabolic panels. The expert consensus panel has agreed on using n-3 PUFAs in MDD treatment for pregnant women, children, and the elderly, and prevention in high-risk populations. Personalizing the clinical application of n-3 PUFAs in subgroups of MDD with a low Omega-3 Index or high levels of inflammatory markers might be regarded as areas that deserve future research.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.